Second-Trimester Bleeding in a Patient Who Declines Transfusion
A 34-year-old G3P1011 at 23 weeks 2 days presents to labor and delivery with painless bright red vaginal bleeding that began 3 hours ago; she soaked two pads. She has had one prior cesarean for breech. Vital signs: BP 118/72, HR 96, temp 36.9 C, RR 16. Fundal height 24 cm. The uterus is soft and nontender. Speculum exam shows blood in the vault with a closed cervix; no active spurting is seen. Bedside ultrasound shows a singleton fetus with a posterior placenta previa and a 2.1 cm cervical length; no retroplacental clot is identified. Fetal heart tones are 145 bpm with a reactive tracing. Hemoglobin is 10.4 g/dL and she has type O negative blood. She is a Jehovah's Witness and states she will not accept allogeneic red cells, platelets, or plasma under any circumstances, and she has a signed refusal document. She is otherwise stable and contracting irregularly every 8 minutes on toco.
1. How should you structure the immediate evaluation and disposition, and what specifically must you clarify about her refusal before she decompensates?
Read the worked answer
The presentation is most consistent with a major placenta previa with a threatened preterm hemorrhage at 23+2 weeks, with irregular contractions that could escalate bleeding. Key moves:
- Stabilize and monitor: continuous fetal monitoring, IV access with two large-bore lines, type and screen/crossmatch (even if she refuses products, the sample and antibody status matter and the blood bank must be notified), serial CBC and coagulation studies, and quantitative blood loss tracking.
- Tocolysis decision: avoid escalating tocolysis that masks ongoing hemorrhage; short-course indomethacin or nifedipine may be considered for contraction control if bleeding is minimal, but the priority is maternal stability, not pregnancy prolongation at all costs.
- Antenatal corticosteroids: at 23+2 weeks, betamethasone is indicated for fetal lung maturity and reduces neonatal morbidity; this is a fetal-directed therapy she has not refused.
- Clarify the refusal scope in writing and in real time: distinguish refusal of allogeneic blood products from acceptance of cell salvage, acute normovolemic hemodilution, erythropoietin, iron, tranexamic acid, and volume expanders. Ask specifically whether she accepts autologous salvage during cesarean and whether she would accept products in an imminently life-threatening situation (many Witness patients sign a durable power of attorney limiting consent). Document her answers verbatim, involve the blood bank and ethics/anesthesia early, and identify her healthcare proxy.
- Disposition: admit to a facility with 24-hour obstetric anesthesia, ICU capability, and blood bank; if this hospital cannot provide that, transfer before she bleeds. A previa with a prior cesarean also raises concern for placenta accreta spectrum - arrange targeted ultrasound/MRI and plan delivery at a center with a multidisciplinary accreta team.
2. She bleeds heavily 6 hours later, HR 128, BP 92/54, and the fetal tracing shows recurrent late decelerations. She continues to refuse blood. What is your management sequence, and how do you weigh maternal versus fetal interests?
Read the worked answer
This is acute life-threatening hemorrhage with maternal hypoperfusion and fetal compromise. Maternal resuscitation takes absolute priority because fetal oxygenation depends entirely on maternal hemodynamics.
Sequence:
- Call for help: activate massive hemorrhage protocol, obstetrics, anesthesia, ICU, and ethics; notify the blood bank and the operating room.
- Resuscitate with what she accepts: crystalloid and colloid, tranexamic acid 1 g IV (reduces mortality in obstetric hemorrhage), cell salvage if she has agreed, vasopressors to maintain uterine perfusion, and correction of coagulopathy with fibrinogen concentrate or other non-blood alternatives per her stated preferences.
- Expedite delivery: with maternal instability and nonreassuring fetal status, proceed to cesarean delivery - do not delay for steroids or expectant management. At 23 weeks the neonate is periviable; involve neonatology for a shared decision, but the indication here is maternal, not fetal.
- Surgical control: anticipate accreta spectrum given prior cesarean and previa; have a senior surgeon, ureteral stents considered, and a plan for hysterectomy or conservative measures. Uterotonics, balloon tamponade, and compression sutures are all appropriate.
- Escalate the refusal conversation only through the proper channel: if she becomes incapacitated, follow her documented advance directive and durable power of attorney. Do not override a competent adult's refusal; if she is incapacitated and the proxy's authority is unclear, engage ethics and legal in real time.
Maternal vs fetal interests: the fetus cannot be prioritized over a dying mother. The ethically and clinically correct framing is that delivering the fetus and controlling hemorrhage serves both - but if forced to choose, maternal life and autonomy prevail. Document the reasoning contemporaneously.